Pipeline
Our pipeline includes four product candidates in clinical development and two additional programs in preclinical testing. Our product candidates address diseases that are not well served by currently available therapies and represent large potential commercial market opportunities. We believe that our product candidates offer innovative therapeutic approaches and may provide significant advantages relative to current therapies.
Our most advanced product candidate is pimavanserin, which is in Phase III development for Parkinson's disease psychosis. Our other clinical-stage products include an alpha adrenergic program for chronic pain and a muscarinic program for glaucoma both in collaboration with Allergan, and AM-831 for schizophrenia in collaboration with Meiji Seika Pharma. In addition, we have preclinical programs directed at Parkinson’s disease and other neurological disorders.
Please click on the sub-links to this page to learn more about our product candidates and the targeted disease areas.
back to top